Which Cholesterol-Lowering Medications Are Most Effective—and How to Choose Between Seletracetam (Sesme) and Statins?

When managing elevated cholesterol levels—particularly high low-density lipoprotein cholesterol (LDL-C)—clinicians often consider combination pharmacotherapy to achieve guideline-recommended targets. Two major classes of lipid-lowering agents frequently used together are statins and selective cholesterol absorption inhibitors. Among the latter, bempedoic acid (marketed in China as Saiximei®) and ezetimibe are well-established options; however, recent regulatory approvals have expanded the landscape with newer agents such as bempedoic acid/ezetimibe fixed-dose combinations.

Bempedoic acid (brand name Saiximei® in China) is a first-in-class ATP-citrate lyase (ACL) inhibitor that reduces hepatic cholesterol synthesis upstream of HMG-CoA reductase—the target of statins. Unlike statins, it is activated only in the liver and does not undergo significant skeletal muscle metabolism, resulting in a lower risk of myalgia and other muscle-related adverse effects. Clinical trials—including the CLEAR Harmony and CLEAR Wisdom studies—demonstrated that bempedoic acid lowers LDL-C by approximately 17–28% as monotherapy and provides additive reductions when combined with moderate-intensity statins.

Statins remain the cornerstone of LDL-C lowering therapy due to robust cardiovascular outcome data. Agents such as atorvastatin, rosuvastatin, and simvastatin significantly reduce LDL-C (by 30–60%, depending on dose and potency) and have proven benefits in reducing major adverse cardiovascular events (MACE) across primary and secondary prevention populations. However, statin intolerance—most commonly due to myalgia or elevated transaminases—occurs in up to 10–15% of patients, limiting adherence and therapeutic efficacy.

The choice between initiating bempedoic acid (e.g., Saiximei®) versus intensifying or switching statin therapy depends on several clinical factors: baseline LDL-C level, cardiovascular risk stratification (e.g., ASCVD risk score or presence of established atherosclerotic disease), prior statin tolerance, concomitant medications (notably those affecting CYP450 metabolism), and renal or hepatic function. For patients with statin intolerance or suboptimal LDL-C control despite maximally tolerated statin therapy, adding bempedoic acid—or using a fixed-dose combination with ezetimibe—is supported by current guidelines, including those from the Chinese Society of Cardiology and the American College of Cardiology/American Heart Association.

It is important to emphasize that pharmacologic intervention should always be embedded within comprehensive cardiovascular risk management: lifestyle modification (heart-healthy diet, regular physical activity, smoking cessation), blood pressure and glucose control, and assessment for secondary causes of dyslipidemia. Shared decision-making—discussing efficacy, safety profiles, dosing convenience, and out-of-pocket costs—is essential to optimize long-term adherence and outcomes.